FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048280013> ?p ?o ?g. }

• W3048280013 abstract "Abstract Background Scale-up of hepatitis C virus (HCV) treatment for HIV/HCV coinfected individuals is occurring in Spain, the vast majority (> 85%) with a reported history of injecting drug use and a smaller population of co-infected men who have sex with men (MSM). We assess impact of recent treatment scale-up to people living with HIV (PLWH) and implications for achieving the WHO HCV incidence elimination target (80% reduction 2015–2030) among PLWH and overall in Andalusia, Spain, using dynamic modeling. Methods A dynamic transmission model of HCV/HIV coinfection was developed. The model was stratified by people who inject drugs (PWID) and MSM. The PWID component included dynamic HCV transmission from the HCV-monoinfected population. The model was calibrated to Andalusia based on published data and the HERACLES cohort (prospective cohort of HIV/HCV coinfected individuals representing > 99% coinfected individuals in care in Andalusia). From HERACLES, we incorporated HCV treatment among diagnosed PLWH of 10.5%/year from 2004 to 2014, and DAAs at 33%/year from 2015 with 94.8% SVR. We project the impact of current and scaled-up HCV treatment for PLWH on HCV prevalence and incidence among PLWH and overall. Results Current treatment rates among PLWH (scaled-up since 2015) could substantially reduce the number of diagnosed coinfected individuals (mean 76% relative reduction from 2015 to 2030), but have little impact on new diagnosed coinfections (12% relative reduction). However, DAA scale-up to PWLH in 2015 would have minimal future impact on new diagnosed coinfections (mean 9% relative decrease from 2015 to 2030). Similarly, new cases of HCV would only reduce by a mean relative 29% among all PWID and MSM due to ongoing infection/reinfection. Diagnosing/treating all PLWH annually from 2020 would increase the number of new HCV infections among PWLH by 28% and reduce the number of new HCV infections by 39% among the broader population by 2030. Conclusion Targeted scale-up of HCV treatment to PLWH can dramatically reduce prevalence among this group but will likely have little impact on the annual number of newly diagnosed HIV/HCV coinfections. HCV microelimination efforts among PWLH in Andalusia and settings where a large proportion of PLWH have a history of injecting drug use will require scaled-up HCV diagnosis and treatment among PLWH and the broader population at risk." @default.
• W3048280013 created "2020-08-13" @default.
• W3048280013 creator A5002616190 @default.
• W3048280013 creator A5006610363 @default.
• W3048280013 creator A5013551077 @default.
• W3048280013 creator A5018970150 @default.
• W3048280013 creator A5025127854 @default.
• W3048280013 creator A5029391761 @default.
• W3048280013 creator A5041759120 @default.
• W3048280013 creator A5047648265 @default.
• W3048280013 creator A5073614180 @default.
• W3048280013 creator A5077472923 @default.
• W3048280013 creator A5086992958 @default.
• W3048280013 date "2020-08-08" @default.
• W3048280013 modified "2023-10-15" @default.
• W3048280013 title "What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis" @default.
• W3048280013 cites W1177621313 @default.
• W3048280013 cites W1635447217 @default.
• W3048280013 cites W1637454162 @default.
• W3048280013 cites W2006747389 @default.
• W3048280013 cites W2021874471 @default.
• W3048280013 cites W2022031150 @default.
• W3048280013 cites W2088894132 @default.
• W3048280013 cites W2097405564 @default.
• W3048280013 cites W2110117592 @default.
• W3048280013 cites W2123209718 @default.
• W3048280013 cites W2127185476 @default.
• W3048280013 cites W2135983610 @default.
• W3048280013 cites W2136526938 @default.
• W3048280013 cites W2143398474 @default.
• W3048280013 cites W2145987628 @default.
• W3048280013 cites W2147943363 @default.
• W3048280013 cites W2152505869 @default.
• W3048280013 cites W2159223590 @default.
• W3048280013 cites W2332403844 @default.
• W3048280013 cites W2343155368 @default.
• W3048280013 cites W2519838946 @default.
• W3048280013 cites W2545076801 @default.
• W3048280013 cites W2612400889 @default.
• W3048280013 cites W2734089729 @default.
• W3048280013 cites W2734667979 @default.
• W3048280013 cites W2753609137 @default.
• W3048280013 cites W2770394506 @default.
• W3048280013 cites W2770470504 @default.
• W3048280013 cites W2772328719 @default.
• W3048280013 cites W2794944046 @default.
• W3048280013 cites W2905685312 @default.
• W3048280013 cites W4247810375 @default.
• W3048280013 doi "https://doi.org/10.1186/s12879-020-05285-z" @default.
• W3048280013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7414743" @default.
• W3048280013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32770955" @default.
• W3048280013 hasPublicationYear "2020" @default.
• W3048280013 type Work @default.
• W3048280013 sameAs 3048280013 @default.
• W3048280013 citedByCount "2" @default.
• W3048280013 countsByYear W30482800132021 @default.
• W3048280013 countsByYear W30482800132022 @default.
• W3048280013 crossrefType "journal-article" @default.
• W3048280013 hasAuthorship W3048280013A5002616190 @default.
• W3048280013 hasAuthorship W3048280013A5006610363 @default.
• W3048280013 hasAuthorship W3048280013A5013551077 @default.
• W3048280013 hasAuthorship W3048280013A5018970150 @default.
• W3048280013 hasAuthorship W3048280013A5025127854 @default.
• W3048280013 hasAuthorship W3048280013A5029391761 @default.
• W3048280013 hasAuthorship W3048280013A5041759120 @default.
• W3048280013 hasAuthorship W3048280013A5047648265 @default.
• W3048280013 hasAuthorship W3048280013A5073614180 @default.
• W3048280013 hasAuthorship W3048280013A5077472923 @default.
• W3048280013 hasAuthorship W3048280013A5086992958 @default.
• W3048280013 hasBestOaLocation W30482800131 @default.
• W3048280013 hasConcept C119599485 @default.
• W3048280013 hasConcept C120665830 @default.
• W3048280013 hasConcept C121332964 @default.
• W3048280013 hasConcept C126322002 @default.
• W3048280013 hasConcept C127413603 @default.
• W3048280013 hasConcept C142462285 @default.
• W3048280013 hasConcept C144024400 @default.
• W3048280013 hasConcept C149923435 @default.
• W3048280013 hasConcept C159047783 @default.
• W3048280013 hasConcept C190139176 @default.
• W3048280013 hasConcept C2522874641 @default.
• W3048280013 hasConcept C2776408679 @default.
• W3048280013 hasConcept C2776455275 @default.
• W3048280013 hasConcept C2776939746 @default.
• W3048280013 hasConcept C2776983459 @default.
• W3048280013 hasConcept C2777813720 @default.
• W3048280013 hasConcept C2777931914 @default.
• W3048280013 hasConcept C2908647359 @default.
• W3048280013 hasConcept C2993143319 @default.
• W3048280013 hasConcept C3013748606 @default.
• W3048280013 hasConcept C61511704 @default.
• W3048280013 hasConcept C71924100 @default.
• W3048280013 hasConcept C72563966 @default.
• W3048280013 hasConcept C761482 @default.
• W3048280013 hasConcept C99454951 @default.
• W3048280013 hasConceptScore W3048280013C119599485 @default.
• W3048280013 hasConceptScore W3048280013C120665830 @default.
• W3048280013 hasConceptScore W3048280013C121332964 @default.
• W3048280013 hasConceptScore W3048280013C126322002 @default.
• W3048280013 hasConceptScore W3048280013C127413603 @default.

• next